Market revenue in 2023 | USD 974.5 million |
Market revenue in 2030 | USD 3,165.1 million |
Growth rate | 18.3% (CAGR from 2023 to 2030) |
Largest segment | Oncolytic virotherapy |
Fastest growing segment | Oncolytic Virotherapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncolytic Virotherapy |
Key market players worldwide | Abeona Therapeutics Inc, Asklepios, Bluebird bio Inc, Celgene, Avidity Biosciences Inc Ordinary Shares, GlaxoSmithKline, Genelux Corp, Gen Digital Inc, Protagonist Therapeutics Inc, Merck KGaA, Onconetix Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer gene therapy market will help companies and investors design strategic landscapes.
Oncolytic virotherapy was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific cancer gene therapy market based on oncolytic virotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cancer gene therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cancer gene therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account